Beta Bionics, Inc. (NASDAQ: BBNX) reported first‑quarter 2026 results on April 21, 2026, posting net sales of $27.6 million, a 57% year‑over‑year increase, and a net loss per share of $0.49, slightly better than the consensus estimate of $0.50. The company’s gross margin expanded to 59.5% from 50.9% in Q1 2025, driven by a shift toward higher‑margin pharmacy‑reimbursed sales and improved production scale.
Revenue growth was largely powered by a 181% year‑over‑year rise in pharmacy benefit plan (PBP) channel net sales, while durable medical equipment (DME) sales grew at a more modest pace. The mix shift to pharmacy‑reimbursed sales, now expected to account for 37%–39% of new patient starts versus 36%–38% previously, helped lift gross margin and supports the company’s strategy of building a recurring revenue base.
Management raised its full‑year 2026 revenue guidance to $131 million–$136 million, up from the prior $130 million–$135 million range, and lifted the gross‑margin outlook to 57.5%–59.5% from 55.5%–57.5%. The guidance increase reflects stronger‑than‑expected demand and the continued mix shift, signaling confidence in sustaining growth momentum and margin expansion.
The company noted a seasonal decline in new patient starts of 10%–20% from Q4 2025 to Q1 2026 and is actively addressing an FDA warning letter concerning quality‑system issues. These headwinds underscore the need for ongoing operational discipline while the company pursues its pipeline initiatives, including the Mint patch pump and bihormonal system.
"We're pleased to share with you all today our financial results for the first quarter as well as positive updates to our full‑year guidance for 2026," said Sean Saint, President and CEO. "In Q1, the company continued to progress rapidly across our key initiatives—both commercially, in terms of driving adoption of the iLet and expanding pharmacy channel access, and developmentally in terms of advancing our Mint patch pump program and bihormonal program."
"We now project total revenue for the year to be $131 million to $136 million, up from our prior guidance of $130 million to $135 million," added Stephen Feider, CFO. "On gross margin, we are raising our outlook to 57.5% to 59.5% for the full year versus our prior guidance of 55.5% to 57.5%."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.